Evotec SE (NASDAQ:EVO - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $4.01, but opened at $3.84. Evotec shares last traded at $3.94, with a volume of 25,256 shares trading hands.
Analysts Set New Price Targets
A number of research firms have commented on EVO. Deutsche Bank Aktiengesellschaft upgraded Evotec from a "sell" rating to a "hold" rating in a research report on Thursday, April 24th. Royal Bank of Canada reiterated an "outperform" rating on shares of Evotec in a research report on Thursday, May 15th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $5.93.
View Our Latest Stock Report on EVO
Evotec Stock Performance
The business has a 50-day simple moving average of $3.75 and a 200 day simple moving average of $4.18. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in EVO. DCF Advisers LLC lifted its stake in shares of Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after purchasing an additional 12,816 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Evotec in the 4th quarter valued at about $27,000. Bank of America Corp DE lifted its stake in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after purchasing an additional 9,289 shares during the period. Lighthouse Investment Partners LLC acquired a new position in shares of Evotec in the 4th quarter valued at about $166,000. Finally, CSS LLC IL acquired a new position in shares of Evotec in the 4th quarter valued at about $50,000. 5.81% of the stock is owned by institutional investors and hedge funds.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Articles
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
